What is OxyDial?
OxyDial Inc. operates at the intersection of advanced medical instrumentation and cloud-based data analytics. The company is currently finalizing the development of its flagship Oxygen-Hemoglobin Equilibrium blood testing instrument, a device engineered to provide rapid, portable, and high-precision diagnostics. By integrating this hardware with a robust cloud platform, OxyDial aims to streamline workflows for healthcare providers and researchers specializing in genetic diseases and complex blood disorders. The firm's market position is defined by its commitment to simplifying diagnostic accessibility, effectively bridging the gap between laboratory-grade accuracy and point-of-care convenience. As the company transitions from the development phase to commercialization, its focus remains on delivering scalable solutions that address the critical needs of modern medical research and patient care environments.
How much funding has OxyDial raised?
OxyDial has raised a total of $700K across 1 funding round:
Private Equity
$700K
Private Equity (2026): $700K, investors not publicly disclosed
Key Investors in OxyDial
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for OxyDial?
With this major enterprise-level funding, OxyDial is poised to scale its manufacturing capabilities and expand its clinical validation studies. The strategic allocation of capital will likely prioritize the finalization of the cloud platform infrastructure, ensuring seamless data integration for institutional clients. Furthermore, the company is expected to bolster its commercial outreach, targeting key research facilities and healthcare networks that require high-throughput, portable diagnostic tools. By leveraging this financial backing, OxyDial is well-positioned to navigate the regulatory landscape and establish a dominant footprint in the global diagnostics market, ultimately setting a new standard for blood disorder monitoring and genetic disease research.
See full OxyDial company page
